Florida/USVI Poison Information Center - Jacksonville, UF Health - Jacksonville/University of Florida Health Science Center, Jacksonville, FL, USA.
Center for Health Equity and Quality Research, UF Health - Jacksonville, Jacksonville, FL, USA.
Clin Toxicol (Phila). 2020 Jan;58(1):49-55. doi: 10.1080/15563650.2019.1605076. Epub 2019 Apr 22.
The purpose of this study was to characterize the frequency, reasons for exposure, clinical manifestations, treatments, duration of effects, and medical outcomes of pediatric guanfacine exposures reported to the National Poison Data System (NPDS) from 2000 to 2016. Data extracted from poison control center call records for pediatric (0-5 years, 6-12 years, and 13-19 years), single-substance guanfacine ingestions reported to NPDS between 2000 and 2016 was retrospectively analyzed. A total of 10927 cases were identified for analysis. Pediatric single-substance guanfacine exposures reported to NPDS increased significantly during the study period, with a marked increase among 6-12-year-olds. The most commonly documented clinical effects across age groups were drowsiness ( = 4262, 39%), bradycardia ( = 1696, 15.5%), and hypotension ( = 1127, 10.3%). The duration of effect for most cases was >8 hours but ≤24 hours (n = 2395, 44.2%). The median documented quantity of guanfacine ingested was 0.11 mg/kg (range: 0.004-7.8 mg/kg). The difference between mg/kg ingested in and groups compared to and groups was statistically significant in all three age groups. Pediatric guanfacine exposures reported to U.S. poison centers have increased significantly in the last fifteen years. The most common clinical findings secondary to guanfacine exposure were bradycardia, hypotension, and CNS depression. There was a statistically significant difference between the mg/kg of guanfacine ingested in the groups experiencing or compared to or effects. However, the maximum ingested dose reported among 0-5-year-olds in the group was 2.72 mg/kg, while the minimum dose eliciting a in both 0-5 and 6-12-year-olds was 0.05 mg/kg. The overall incidence of effects was very low, with the vast majority of patients experiencing minor symptoms or less. Based on this data, we agree with current recommendations that any symptomatic pediatric patient exposed to guanfacine should be observed in a health care facility for at least 24 hours.
本研究旨在描述 2000 年至 2016 年期间向国家毒物数据系统（NPDS）报告的儿科胍法辛暴露的频率、暴露原因、临床表现、治疗、影响持续时间和医疗结果。从 NPDS 报告的 2000 年至 2016 年期间，0-5 岁、6-12 岁和 13-19 岁儿童单一物质胍法辛摄入的中毒控制中心电话记录中提取数据进行回顾性分析。共确定了 10927 例进行分析。在研究期间，向 NPDS 报告的儿科单一物质胍法辛暴露显著增加，6-12 岁儿童的暴露明显增加。各年龄组最常见的临床影响为嗜睡（ = 4262，39%）、心动过缓（ = 1696，15.5%）和低血压（ = 1127，10.3%）。大多数病例的影响持续时间>8 小时但≤24 小时（n = 2395，44.2%）。记录的胍法辛摄入量中位数为 0.11mg/kg（范围：0.004-7.8mg/kg）。与 0-5 岁和 6-12 岁组相比，和 组的儿童胍法辛摄入量之间存在统计学显著差异mg/kg。在过去的十五年中，向美国中毒中心报告的儿科胍法辛暴露量显著增加。胍法辛暴露后的常见临床发现是心动过缓、低血压和中枢神经系统抑制。在经历或 与 或 影响的组之间，胍法辛摄入的 mg/kg 存在统计学显著差异。然而，在组中报告的 0-5 岁儿童最大摄入剂量为 2.72mg/kg，而在 0-5 和 6-12 岁儿童中引起最小的剂量为 0.05mg/kg。的总体发生率非常低，绝大多数患者仅出现轻微症状或症状较轻。根据这些数据，我们同意目前的建议，即任何有症状的儿科患者暴露于胍法辛后，应在医疗机构中至少观察 24 小时。
